Zacks Research Lowers Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for shares of AngioDynamics in a report issued on Wednesday, October 23rd. Zacks Research analyst D. Dey now anticipates that the medical instruments supplier will earn ($0.12) per share for the quarter, down from their previous estimate of ($0.10). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS and FY2027 earnings at ($0.16) EPS.

A number of other equities research analysts also recently weighed in on ANGO. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a report on Friday, October 4th. Canaccord Genuity Group reduced their price objective on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

AngioDynamics Trading Down 5.1 %

NASDAQ ANGO opened at $6.73 on Friday. The firm’s 50 day simple moving average is $7.15 and its 200 day simple moving average is $6.68. The firm has a market capitalization of $269.57 million, a price-to-earnings ratio of -1.39 and a beta of 0.65. AngioDynamics has a 1 year low of $5.26 and a 1 year high of $8.25.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $67.50 million for the quarter, compared to the consensus estimate of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANGO. Quarry LP grew its stake in shares of AngioDynamics by 75.1% in the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 2,594 shares during the last quarter. CWM LLC lifted its holdings in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares during the period. Mackenzie Financial Corp bought a new stake in shares of AngioDynamics in the 2nd quarter valued at about $80,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of AngioDynamics in the third quarter valued at about $86,000. Finally, AE Wealth Management LLC acquired a new stake in shares of AngioDynamics in the second quarter valued at about $87,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insiders Place Their Bets

In other news, CEO James C. Clemmer purchased 20,000 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was bought at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the purchase, the chief executive officer now owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have purchased 22,568 shares of company stock valued at $135,847. 5.10% of the stock is currently owned by insiders.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.